SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is a focal point of market discussion, driven by strong recent housing data like increased pending home sales and falling mortgage rates, alongside its strategic expansion into a broader homeownership platform. The community is fiercely divided, with many accumulating shares on current dips, confident in an impending rebound and profitability goals, while others debate short-term price pressures from tax-loss selling and market dynamics.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

GLSI is trending due to positive preliminary data from its FLAMINGO-01 breast cancer immunotherapy trial, which reported a substantial reduction in recurrence rates. This clinical optimism is significantly bolstered by an extended share lock-up for directors and officers through September 2026, signaling strong insider confidence. The community is actively discussing a potential short squeeze, citing high cost-to-borrow rates and limited share availability, alongside the drug's promising multi-billion dollar market potential.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is trending due to its proposed merger with Applied Digital's cloud computing business to launch ChronoScale, an AI platform. This development has sparked mixed community reactions, with many concerned about significant shareholder dilution, while others are bullish on the new AI focus and its low float. Ongoing discussions also reference its past acceptance into the NVIDIA Connect Program, adding to the speculative interest.

DoubleZero is a high-performance global network of independently contributed links, purpose-built for blockchain and other distributed systems. It provides direct, low-latency routing that strengthens validator performance and supports faster, fairer participation worldwide.  2Z Tokens are used to access the network’s connectivity service, and, on the other side, reward network contributors and resource providers based on performance and reliability. 2Z Tokens can also be staked to enhance the security of the network.

DoubleZero

DoubleZero ($2Z) is trending amidst buzz over new listings on major crypto exchanges, driving significant trading volume and price surges. The community is actively discussing its fiber optics technology, with many anticipating substantial "altseason" gains and FOMO, while some express caution regarding its rapid volatility.

Mannatech, Inc. engages in the development of nutritional supplements, topical and skin care products and weight-management products that target optimal health and wellness. Its product category includes integrative health, targeted health, wealth and fitness, skin care, essentials, and home. The company was founded by Marlin Ray Robbins and Samuel L. Caster in November 1993 and is headquartered in Flower Mound, TX.

Mannatech Inc

Mannatech (MTEX) is trending due to widespread community speculation around its exceptionally low public float, fueling expectations of a potential short squeeze and a rapid parabolic price surge. While many anticipate significant upside and highlight recent improvements in profitability, a strong counter-narrative warns of a pump-and-dump, urging caution despite the accumulating bullish sentiment.

0x (ZRX) is gaining attention following its v2 launch, which enhances swap capabilities and expands its presence across multiple blockchains, coupled with the strategic acquisition of a DEX aggregator. The community actively debates ZRX's foundational utility as "rails" for tokenized assets and major exchanges, with many expressing bullish conviction despite frustration over its price lagging behind other crypto assets. Discussions also highlight the influence of advisor David Sacks, hinting at ZRX's potential in the evolving crypto landscape.

abrdn ETF - abrdn Physical Palladium Shares ETF

PALL is experiencing a notable surge, with traders highlighting strong technical breakouts from a prolonged base. This rally is propelled by ongoing supply concerns from major producing regions and robust demand from the automotive sector, particularly for hybrid vehicles, where Palladium's performance is favored. The community is actively discussing its extreme rarity and potential for substantial further gains as it re-rates within the current precious metals bull market.

DigitalBridge Group, Inc. is a global alternative asset manager, which engages in investing in digital infrastructure. The firm focuses on operating businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure. It operates through the following segments: Investment Management, Operating, and Corporate and Other. The Investment Management segment represents the global investment management platform, deploying, and managing capital on behalf of a diverse base of global institutional investors. The Operating segment refers to the digital infrastructure and real estate operating companies, which generally earn rental income from providing use of digital asset space and capacity through leases, services, and other agreements. The Corporate and Other segment includes investment and corporate level activities. The company was founded in 1991 and is headquartered in Boca Raton, FL.

DigitalBridge Group Inc - Ordinary Shares - Class A

DigitalBridge is actively trending following confirmed news of its acquisition by SoftBank Group for $16 per share, a move that underscores robust demand for AI-driven digital infrastructure. However, the community is largely disappointed, widely viewing the offer as undervalued and speculating on the possibility of a higher bid or shareholder pushback. This development reinforces the critical role of data centers in the ongoing AI revolution, even as investors weigh the deal's fairness.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

BriaCell Therapeutics Corp

BriaCell Therapeutics is trending amid intense investor debate following a new public offering and a recent reverse stock split, which have fueled significant frustration over perceived dilution. Counteracting this sentiment, the company has released promising Phase 3 clinical data, secured an NCI grant, and received recognition in Nature Medicine, reinforcing optimism among some about its potential in cancer immunotherapy. The community remains sharply divided between skepticism toward financial management and excitement for the therapeutic pipeline's advancements.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx (RARE) is trending due to the unexpected failure of its late-stage brittle-bone disease drug setrusumab to meet its primary efficacy endpoint, triggering a significant sell-off and widespread investor concern. Despite a terrible balance sheet and analyst downgrades, a notable contingent views the sharp decline as an overreaction, highlighting the company's existing portfolio of revenue-generating products and other pipeline catalysts. The broader biotech community is actively debating whether the stock is now oversold, with some pointing to upcoming regulatory milestones for other therapies as potential drivers for a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
